Phase I Open-label Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs ONC1 13B (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Avionco
- 08 Jul 2017 Status changed from active, no longer recruiting to completed.
- 08 Nov 2013 New trial record